Auxilium rejects Endo's $2.2bn offer, keeps QLT merger alive
This article was originally published in Scrip
Executive Summary
The Auxilium Pharmaceuticals board of directors unanimously rejected Endo International's $2.2bn offer to buy the company in favor of its previously negotiated all-stock merger with QLT, showing a preference for tax inversion over a substantial return on investors' shares.